Low serum free triiodothyronine level predicts worse outcome of patients with severe fever with thrombocytopenia syndrome

Li Wang*, Youde Liu, Haifeng Yu, Kun Ding and Zhiqiang Zou*

Abstract

Background: Severe fever with thrombocytopenia syndrome (SFTS) caused by phlebovirus results in neuropsychiatric symptoms, multiorgan dysfunction and significant mortality. We aimed to evaluate the thyroid function in SFTS patients, elucidate its association with neuropsychiatric manifestations, disease severity, and prognosis, retrospectively.

Methods: Serum levels of free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) were compared between survivors and non-survivors, between those with and without nervous symptoms at baseline, and at baseline and remission. Logistic regression analysis was utilized to determine independent risk factors for mortality. A risk model based on risk factors was constructed and its prognostic value was evaluated by receiver operating characteristic (ROC) curve.

Results: A total of 207 SFTS cases with thyroid function data enrolled from January 2016 to January 2020 were included with 34 patients (16.4%) died. Baseline serum levels of FT3, TSH (p < 0.001), and FT3/FT4 ratio (p < 0.05) were significantly decreased in nonsurvivors than in survivors. Prevalence of low serum FT3 in nonsurvivors (81.8%) was greater than in survivors (41.3%). FT3 level (p < 0.001) was markedly reduced in patients with central neurological symptoms than those without. FT3 and FT4 levels were increased in remission than at baseline (p < 0.001). Logistic regression analysis showed that age (OR 0.92, 95% CI 0.868–0.958) and serum FT3 level (OR 3.055, 95% CI 1.494–6.248) were the independent risk factors for mortality. A risk model based on age and FT3 had a high predictive value for mortality (AUC = 0.818, 95% CI 0.795–0.868) at a cutoff value of > 3.39.

Conclusions: Low serum FT3 level was associated with a worse outcome of SFTS patients.

Keywords: Severe fever with thrombocytopenia syndrome, Thyroid function, Nervous symptom, Outcome

Background

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging virus infectious disease caused by SFTS virus (SFTSV), a novel tick-borne bunyavirus of the genus Phlebovirus and family Phenuiviridae. SFTS has been reported endemic in some of Eastern Asia and Southeast Asia countries, including China, Korea, and Japan, which has a high mortality rate in humans [1]. Clinical symptoms of SFTS involve multi-organ dysfunction manifestations. Central nervous system (CNS) injury presented as acute encephalopathy/encephalitis symptoms are a severe and common complication of SFTS, mainly including headache, confusion and seizure [2]. It has been reported that approximately 19% of SFTS patients developed encephalitis and fatal outcome occurred in 44.7% of these patients [3].
The exact mechanisms of SFTS-associated encephalopathy/encephalitis (SFTSAE) were unclear. Several factors have been suggested to be associated with pathogenesis of SFTSAE, including direct invasion of SFTSV in the CNS [4] and proinflammatory cytokine storm induced inflammatory response in the CNS [5]. While other manifestations, such as apathy, slurred speech, and limb tremors cannot be fully explained by SFTSAE. It has been proposed that SFTSV infection triggered cytokine storm highly resembles the immune activation seen in sepsis [6], and sepsis is often accompanied by thyroid dysfunction called "low triiodothyronine (T3) syndrome" which greatly affects the prognosis of patients [7]. Furthermore, development of peripheral and central neuropsychiatric symptoms [8]. Decreased conduction velocity and sensory function of the tibial and peroneal nerves observed in hypothyroid patients were also present in SFTS patients which might account for neuro-muscular symptoms [9].

Whereas the prevalence of thyroid dysfunction and low T3 syndrome in SFTS has not yet been evaluated. In this study, we intended to assess the incidence of low T3 syndrome in SFTS and its association with neuropsychiatric manifestations, severity of the disease and mortality.

**Patients and methods**

**Patients diagnosis and symptom evaluation**

Two hundred and seven SFTS patients admitted to our hospital from January 2016 to December 2020 who have thyroid function test results were included. Diagnosis of SFTS was confirmed by detected positive SFTSV from peripheral blood samples using reverse transcription–polymerase chain reaction (RT–PCR). Demographic and physiological parameter including age, gender, body temperature, pulse, respiratory rate and blood pressure were collected at admission. Serum free T3 (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) were detected using an automatic chemiluminescence immunoanalyzer (Mindray CL-6000i). Timing points of estimation of FT3, FT4 and TSH were selected on admission and remission for survivors and only on admission for nonsurvivors due to their short hospital stays. Serum biochemical parameters were assayed by Beckman AU5800 automatic biochemical analyzer.

Central neuropsychiatric symptoms and peripheral motor nerve symptoms were evaluated by careful physical examinations. Patients were divided into different groups according to survival state, or whether with or without central neuropsychiatric symptoms and peripheral motor nerve symptoms. Thirty old individuals with no significant cardiovascular disease, endocrine diseases and SFTSV infection who underwent health physical examination were included as controls.

This study was performed according to the Helsinki II Declaration and was approved by the ethics committee of Qishan (Infectious Disease) hospital of Yantai, Shandong, China (Ethics number 202201).

**Statistical analysis**

Data are presented as mean ± SD or median (Q25–Q75). The student t test or paired t test, Mann–Whitney U test or paired nonparametric test and one-way ANOVA were used for the comparison of variables between or among groups. Proportions of variables between groups were compared using χ² tests. Correlation analysis was done using Spearman's correlation analysis. Multivariate and univariate logistic regression analysis were used to obtain independent risk factors associated with mortality. A risk model based on these independent risk factors was established. Area under the receiver operating characteristic curve (ROC) (AUC) with the highest Youden index was used to evaluate the prognostic values of these factors and the model. The KaplanMeier survival analysis was utilized to compare the cumulative risk for mortality using the log-rank test. SPSS software (version 23.0, IBM, Armonk, NY, USA) and MedCalc software were used for statistical analysis and p values <0.05 were considered significant.

**Results**

**Comparison of demographics and baseline biochemical and thyroid function parameters between survivors, nonsurvivors and normal controls**

Of 207 SFTS patients, 34 (16.4%) died. Mean age of non-survivors (71.4 ± 10.8 years) was greater than survivors (60.9 ± 10.9 years) (p < 0.0001). Percentage of male patients in nonsurvivors (73.5%) was greater than in survivors (43.6%) (p < 0.05). Serum levels of FT3 and TSH and FT3/FT4 ratio were decreased dramatically in nonsurvivors compared with those in survivors. Serum levels of FT3 and FT4 and FT3/FT4 ratio were reduced profoundly in survivors and non-survivors compared with those in controls. Prevalence of low serum FT3 in survivors, nonsurvivors and controls were 41.3%, 81.8% and 6.7%, respectively (p < 0.0001). Though TSH level has no significant difference between survivors and healthy controls, it is remarkably lower in nonsurvivors lower than in controls. Incidence of nervous symptoms Serum level of Hs-CRP and pulse number were greater in nonsurvivors than in survivors. Incidence of neurological symptoms (%) for survivors and nonsurvivors were 36.4% and 88.2%, respectively (p < 0.0001). Data are presented in Table 1 and Fig. 1a–c.
Comparison of parameters of thyroid function between males and females in survivors and nonsurvivors

Mean age between males and females in survivors and non-survivors had no significant difference. Among thyroid function parameters, only FT3 was decreased markedly in females [2.66 (2.13, 3.36)] in comparison with that in males [2.92 (2.33, 3.50)] in survivors (p = 0.033) which suggested that difference of FT3 level between male and female patients had no association with SFTS prognosis. Data are indicated in Table 2.

Comparison of parameters of thyroid function at baseline and remission in survivors

Serum FT3 and FT4 levels were elevated significantly at remission in comparison with at baseline in the same cohort of patients. Whereas, FT3 level in remission was still markedly lower than controls. FT4 level was comparable with controls in remission. Serum levels of TSH had no significant difference among baseline, remission and controls. Other biochemical parameters, including creatine kinase (CK), CKMB, hydroxybutyrate dehydrogenase (HBDH) and lactate dehydrogenase (LDH) were also decreased dramatically at remission comparing with at baseline. Data are summarized in Table 3 and Fig. 1d–f.

A total of 4 patients tested for thyroid function 3 times at admission, remission and recovery, respectively (Fig. 2). Levels of FT3 and FT4 elevated gradually, while TSH level in two of these patients elevated in remission and dropped sharply in recovery.

Thyroid functions in patients with and without symptoms of central or peripheral nervous system dysfunction in survivors

Mean age of patients with central nervous system symptoms was greater than that of those with peripheral nervous symptoms and without nervous symptoms (p < 0.01). Serum FT3 level in patients with central neuropsychiatric symptom was much less than that in those other two groups. Though levels of FT4 and TSH in patients with peripheral and central nervous symptoms were comparable, FT3/FT4 ratio was greater in the former than in the latter (p < 0.05).

Table 1 Comparison of baseline FT3, FT4, FT3/FT4 ratio, TSH, biochemical indicators and physical parameters in survivors and nonsurvivors [mean ± SD or median (Q25–Q75)]

| Parameters               | Survivors         | Nonsurvivors      | Controls       | p value   |
|--------------------------|-------------------|-------------------|----------------|-----------|
| N (%)                    | 173 (83.6)        | 34 (16.4)         | 30             | –         |
| Age (year)               | 60.9 ± 10.9###   | 71.4 ± 10.8###   | 55.1 ± 8.1     | < 0.0001  |
| M/F (%)                  | 84/89 (48.6/51.4) | 25/9 (73.5/26.5) | 13/17 (43.3/56.7) | 0.013     |
| FT3 (pmol/L)             | 2.78 (2.25, 3.44### | 2.24 ± 0.42### | 4.40 ± 0.83     | < 0.0001  |
| Prevalence of low serum FT3 (%) | 71/172 (41.3)### | 27/33 (81.8)### | 2/30 (6.7)     | < 0.0001  |
| FT4 (pmol/L)             | 11.05 (9.93, 11.15### (n = 100) | 10.87 ± 2.08### (n = 26) | 14.23 ± 2.01 | 0.37      |
| FT3/FT4 ratio            | 0.25 ± 0.06### (n = 100) | 0.22 ± 0.06### (n = 26) | 0.32 ± 0.07     | 0.016     |
| TSH ( ulU/ml)            | 1.37 (0.89, 1.96) (n = 98) | 0.61 (0.41, 1.06)### (n = 24) | 1.11 (0.86,1.72) | < 0.0001  |
| TCH (mmol/L)             | 3.5 (3.0, 4.18)   | 3.2 (2.6, 3.9)    | –              | 0.084     |
| Hs-CRP (mmol/L)          | 5 (1.8,13.3)     | 9 (5,3,41.0)      | –              | 0.008     |
| Pulse (beats/min)        | 74 (67,82)        | 84.0 ± 11.6       | –              | < 0.0001  |
| Baseline body temperature (℃) | 37.2 (36.3, 38.3) | 37.5 (36.7, 38.5) | –              | 0.233     |
| Highest body temperature (℃) | 38.9 (38.5, 39)   | 39 (38.5,39.2)   | –              | 0.42      |
| Ctnl (pg/ml)             | 0.41 (0.03, 33.5) | 23.9 (0.25, 214.6) | –              | 0.011     |
| CK(U/L)                  | 473 (178.9, 1027.4) | 1199.5 (485.3, 3523.5) | –              | 0.001     |
| LDH(U/L)                 | 575.0 (386.1, 867.2) | 942.2 (636.6, 1302.8) | 0.464         | 0.004     |
| HBDH(U/L)                | 404.3 (280.6, 566.8) | 594.6 (438.1, 1114.3) | 0.002         | 0.001     |
| Incidence of neurological symptoms (%) | 63/173 (36.4) | 30/34 (88.2) | < 0.0001     |

*Comparison between survivors and non-survivors

### p < 0.001, **p < 0.01, *p < 0.05 in comparison with control

FT3 free triiodothyronine; FT4 free tetraiodothyroxine; TSH thyroid stimulating hormone; TCH total cholesterol; Hs-CRP high-sensitivity C-reactive protein; MAP mean arterial pressure; Ctnl cardiac troponin; CK Creatine kinase; LDH lactate dehydrogenase; HBDH hydroxybutyrate dehydrogenase

Mean age between males and females in survivors and non-survivors had no significant difference. Among thyroid function parameters, only FT3 was decreased markedly in females [2.66 (2.13, 3.36)] in comparison with that in males [2.92 (2.33, 3.50)] in survivors (p = 0.033) which suggested that difference of FT3 level between male and female patients had no association with SFTS prognosis. Data are indicated in Table 2.

Comparison of parameters of thyroid function between males and females in survivors and nonsurvivors

Comparison of parameters of thyroid function at baseline and remission in survivors

Comparison of thyroid functions in patients with and without symptoms of central or peripheral nervous system dysfunction in survivors

Mean age of patients with central nervous system symptoms was greater than that of those with peripheral nervous symptoms and without nervous symptoms (p < 0.01). Serum FT3 level in patients with central neuropsychiatric symptom was much less than that in those other two groups. Though levels of FT4 and TSH in patients with peripheral and central nervous symptoms were comparable, FT3/FT4 ratio was greater in the former than in the latter (p < 0.05).
Serum Hs-CRP level has no significant difference among these three groups. CK-MB ($p < 0.05$), HBDH and LDH ($p < 0.01$) were increased profoundly in patients with central nervous symptom. Data are given in Table 4.

Correlation between serum Hs-CRP and parameters of thyroid function
In survivors, serum FT3 and TSH levels were correlated negatively with serum hs-CRP level at admission, especially FT3 ($p < 0.0001$). In remission, no significant
correlation was observed between serum hs-CRP and parameters of thyroid function. While in nonsurvivors, no significant correlation between these parameters.

**Independent risk factor obtaining and risk model construction**

Univariate logistic regression analysis showed that age, serum levels of FT3, CK-MB, HBDH and LDH ($p < 0.2$) were independent risk factors for mortality of SFTS patients. Multivariate logistic regression analysis indicated that only age and serum FT3 were the independent risk factors for mortality with odds ratios (OR) (95% CI) were 0.912 (0.868, 0.958) and 3.055 (1.494, 2.658), respectively. Their regression coefficient were 0.093 and −1.117, respectively. Based on age and serum level of FT3, we constructed a risk score model

$$M = 0.093 \times \text{age} - 1.117 \times \text{FT3}$$

for the prediction of mortality (Table 5).

**Predictive values of FT3 and the risk model for the prognosis of SFTS patients**

The cutoff values and AUCs (95% CI) of age, FT3 and the model (M) with sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR−) for predicting mortality of SFTS patients obtained by ROC analysis were included in Table 5 and Fig. 3a–c. Log-rank test of survival analysis showed that the overall survival rate had remarkable difference between low and high value groups at the cutoff values of age, FT3 and the model (M) with the highest Youden index (Fig. 3d–f).

**Discussion**

In this research, we found that the prevalence of low serum FT3 level was higher in nonsurvivors (81.8%) than in survivors (41.3%) (Table 1) and low serum level...
of FT3 was the independent risk factor of mortality for SFTS patients (Table 5). Though the prevalence of low serum FT3 was comparable among patients with central neuropsychiatric, peripheral neurological symptoms and those with no neurological symptoms, serum FT3 level was markedly lower in patients with central neuropsychiatric symptom than those in the other two groups (Table 4) which indicated that degree of low FT3 level was associated with central neuropsychiatric symptom. Consistent with our results, previous studies had demonstrated that development of encephalopathy/encephalitis was associated with worse outcome in SFTS patients [3]. SFTSV genome detected in cerebrospinal fluid (CSF) in SFTS patients suggests that direct invasion of SFTSV in the CNS may play an important role in the pathogenesis of SFTSAE [3]. Our results showed that both of serum FT3 level and TSH level were decreased dramatically in nonsurvivors, which suggested that hormone regulation in hypothalamus-pituitary-thyroid axis was seriously harmed. And SFTSAE may be one of the reasons leading to damage of hypothalamus and pituitary and therefore resulting in hypothyroidism and low serum FT3 level, especially in patients of mortality.

On the other hand, indirect effect of the inflammation and cytokine storm triggered by SFTSV infection also involved in the disturbance of consciousness [3, 4]. Consistent with this, inhibition of systemic inflammation by short-term methylprednisolone pulse therapy resulted in a favorable outcome in some patients. And this remedy led to no long term damage to neurological system [10]. Low FT3 syndrome may also occur in inflammatory response syndrome (SIRS) or sepsis [8, 11]. In line with this, we found that baseline serum FT3, TSH levels and Hs-CRP level were negatively correlated in survivors and no noteworthy correlations were observed between these parameters in remission and in nonsurvivors.

### Table 4  Comparison of baseline FT3, FT4, FT3/FT4 ratio and TSH in patients with and without symptoms of neuropsychiatric dysfunction in survivors

|                      | Without nervous symptom | With central neuropsychiatric symptom | With peripheral neurological symptom |
|----------------------|-------------------------|--------------------------------------|-------------------------------------|
| **Age (year)**       | 59.2 ± 11.4             | 65.4 ± 8.9*                          | 62.7 ± 9.8                          |
| **M/F (%)**          | 54/58 (48.2/51.8)       | 14/18 (43.8/56.2)                    | 16/12 (57.1/42.9)                   |
| **FT3 (pmol/L)**     | 2.89 (2.28, 3.53)       | 2.51 ± 0.75*                         | 2.78 (2.28, 3.58)                   |
|                      | (n = 111)               | (n = 31)                             | (n = 28)                            |
| **Prevalence of low serum FT3 (%)** | 42/111 (37.4)          | 16/31 (51.3)                         | 11/28 (39.3)                        |
| **FT4 (pmol/L)**     | 11.8 ± 2.6              | 11.2 ± 2.3                           | 10.36 (9.73, 13.01)                 |
|                      | (n = 61)                | (n = 20)                             | (n = 18)                            |
| **FT3/FT4 ratio**    | 0.25 ± 0.07             | 0.23 ± 0.07                          | 0.27 ± 0.05*                        |
|                      | (n = 61)                | (n = 20)                             | (n = 18)                            |
| **TSH (uIU/mL)**     | 1.49 (1.00, 2.13)       | 1.18 (0.74, 1.50)                    | 0.84 (0.60, 4.46)                   |
|                      | (n = 60)                | (n = 20)                             | (n = 18)                            |
| **Baseline body temperature (°C)** | 37.5 ± 1.07            | 37.3 ± 1.90                          | 37.5 ± 1.10                         |
| **pulse**            | 74.8 ± 11.1             | 75.8 ± 11.8                          | 72.4 ± 11.4                         |
| **Hs-CRP (mmol/L)**  | 4.65 (1.80, 13.28)      | 6.95 (1.73, 18.08)                   | 5.70 (1.80, 17.28)                  |
| **Ctnl (pg/mL)**     | 0.56 (0.03, 31.2)       | 0.20 (0.03, 39.1)                    | 1.46 (0.07, 45.4)                   |
| **CK (U/L)**         | 469.3 (1568, 952.2)     | 685.9 (1675, 1246.3)                 | 528.4 (276.1, 1208.0)               |
| **CK-MB (U/L)**      | 30.5 (20.1, 44.8)       | 41.4 (24.8, 59.5)                    | 40.3 (25.4, 52.4)                   |
| **HBDH (U/L)**       | 378.6 (264.9, 506.2)    | 553.9 (337.5, 707.7)**               | 410.2 (300.2, 703.9)                |
| **LDH (U/L)**        | 551.7 (355.9, 748.0)    | 844.2 (478.5, 1225.1)**              | 560.0 (401.1, 1039.7)               |

* p < 0.05 **p < 0.01 compared with group without nerve symptom; *p < 0.05 compared with group with central neuropsychiatric symptom

### Table 5  Predictive values of risk factors and risk model (M) for mortality

| Cutoff values | AUC (95% CI) | SEN (%) | SPE (%) | PPV (%) | NPV (%) | LR+ | LR− |
|---------------|-------------|---------|---------|---------|---------|-----|-----|
| **Age (year)** | > 64        | 0.752 (0.687, 0.809) | 78.3 | 61.1 | 21.2 | 95.5 | 2.01 | 0.36 |
| **FT3 (pmol/L)** | < 2.69   | 0.727 (0.660, 0.786) | 87.0 | 55.0 | 20.6 | 96.9 | 1.93 | 0.24 |
| **M**          | > 3.39      | 0.818 (0.759, 0.868) | 82.0 | 73.0 | 39.0 | 96.0 | 2.6  | 0.09 |

AUC area under ROC curve; SEN sensitivity; SPE specificity; PPV positive predictive value; NPV negative predictive value; LR+ positive likelihood ratio; LR− negative likelihood ratio; M risk score model
These results indicated that systemic inflammatory response might play a key role in hypothalamus-pituitary-thyroid axis dysregulation and low FT3 syndrome development in survivors. Furthermore, though FT3 and FT4 levels were elevated significantly in admission than at baseline, TSH levels were still comparable with those at baseline which suggested that it might need a long period for the normalization of the hypothalamus-pituitary-thyroid axis hormone regulation or it might never return to normal regulation.

Nevertheless, our results indicated that low FT3 syndrome was mainly attributed to CNS injury and central hypothyroidism in SFTS patients, it might also be resulted from thyroid injury itself. Previous studies demonstrated that SFTSV antigens and SFTSV-nucleocapsid protein (NP) were positive in multiple organs including the heart, lung, kidney, spleen and CNS detected by immunohistochemistry and immunoblasts [12, 13] which indicated that SFTSV led to systemic infection. We speculate that thyroid can also be infected and results in hypothyroidism which needs further investigation.

It has been shown that hypothyroidism is more common among older people in comparison to the youngsters. Because the hypothalamic-pituitary-thyroid axis and its secreted hormones undergo significant changes with the physiological aging [14]. Our results showed that age of nonsurvivors was greater than that of survivors, and age was an independent risk factor for mortality, which suggested that preexist hypothyroidism might lead to a worse outcome in old patients. A risk model based on the combination of age and serum FT3 had a high prognostic predictive for adverse outcome of SFTS patients.

Thyroid hormones (THs) play an essential role in both the innate and adaptive immune responses [15]. SFTSV infection induced hypothyroidism can in turn result in defective immune responses and aggravate infection leading to a vicious cycle. Here, we propose a potential treatment strategy supplement with THs and other supportive measures for the protection and promotion of recovery of severe hypothyroidism in SFTS.

There are several limitations in our study. Firstly, few second THs testing data were available due to short hospital stays in nonsurvivors which might affect analysis results. Secondly, lack of tissue infection results including thyroid and brain in nonsurvivors. Thirdly, lack of follow-up data of thyroid functions after being discharged from hospital. Fourthly, no data were available on effects of inflammation inhibition on thyroid function due to insufficient patients received
glucocorticoid treatment. Lastly, data of changes of hypothalamus and pituitary hormone levels during SFTS disease course were absent.

Conclusions
In all, low serum FT3 was usually present in SFTS patients and was associated with an adverse outcome. Serum FT3 level was much lower in patients with central neuropsychiatric symptom than that in patients without nervous manifestations. Age and serum FT3 were the independent risk factors associated with mortality of SFTS patients. The risk score model based on them holds a high predictive value for in-hospital mortality.

Abbreviations
AUICs: Area under ROC curve; CNS: Central nervous system; FT3: Free triiodothyronine; FT4: Free thyroxine; hs-CRP: High-sensitivity C-reactive protein; LR+: Positive likelihood ratio; LR−: Negative likelihood ratio; NPV: Negative predictive value; PPV: Positive predictive value; ROC: Receiver-operating characteristic; RT–PCR: Reverse transcription–polymerase chain reaction; SEN: Sensitivity; SPE: Specificity; SFTS: Severe fever with thrombocytopenia syndrome; SFTSV: SFTS virus; TSH: Thyroid stimulating hormone; SFTSAE: SFTS-associated encephalopathy/encephalitis.

Acknowledgements
The authors thank all of the contributors in SFTS diagnosis and treatment.

Author contributions
LW and ZZ conceived and designed the research. LW, HY, and KD collected clinical samples. LW and YL performed the data analysis and modeling. LW wrote the manuscript. All authors reviewed and approved the final manuscript.

Funding
This research was not supported by any specific grant.

Availability of data and materials
All relevant data are within the paper.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethical Committee of Qishan Hospital of Yantai due to the retrospective nature of the study.

Consent for publication
Not applicable.

Competing interests
The authors state that they have no conflict of interest.

Received: 28 June 2021   Accepted: 5 April 2022
Published online: 20 April 2022

References
1. Li H, Lu QB, Xing B, Zhang SF, Liu K, Du J, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011–17: a prospective observational study. Lancet Infect Dis. 2018;18:1127–37.

2. Deng B, Zhou B, Zhang S, Zhu Y, Han L, Geng Y, et al. Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in North-east China. PLoS ONE. 2013;8(11):e80802.

3. Cui N, Liu R, Lu QB, Wang LY, Qin SL, Yang ZD, et al. Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis. J Infect. 2015;70:52–9.

4. Park SY, Kwon JS, Kim JY, Kim SM, Jang YR, Kim MC, et al. Severe fever with thrombocytopenia syndrome-associated encephalopathy/encephalitis. Clin Microbiol Infect. 2018;24:432.e1-432.e4.

5. Bastos MS, Coelho-Do-Res JG, Zauli DA, Naveca FG, Monte RI, Pimentel JP, et al. Divergent cerebrospinal fluid cytokine network induced by non-viral and different viral infections on the central nervous system. BMC Infect Dis. 2015;15:345.

6. Rudd KE, Seymour CW, Aluisio AR, Augustin ME, Bagenda DS, Beane A, et al. Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries. JAMA. 2018;319:2202–11.

7. Luo B, Yu Z, Li Y. Thyroid hormone disorders and sepsis. Biomed Mater Eng. 2017;28(6):S237–41.

8. Kim JG, Shin H, Kim W, Lim TH, Jang B, Cho Y, et al. The value of decreased thyroid hormone for predicting mortality in adult septic patients: a systematic review and meta-analysis. Sci Rep. 2018;8:14137.

9. Gupta N, Arora M, Sharma R, Arora KS. Peripheral and central nervous system involvement in recently diagnosed cases of hypothyroidism: an electrophysiological study. Ann Med Health Sci Res. 2016;6(5):261–6.

10. Nakamura S, Azuma M, Maruhashi T, Sogabe K, Sumitani R, Uemura M, et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. J Infect Chemother. 2018;24:389–92.

11. Lin X, Shi S, Shi S. Sepsis leads to thyroid impairment and dysfunction in rat model. Tissue Cell. 2016;48:511–5.

12. Li S, Li Y, Wang Q, Yu X, Liu M, Xie H, et al. Multiple organ involvement in severe fever with thrombocytopenia syndrome: an immunohistochemical finding in a fatal case. Virol J. 2018;15:97.

13. Kaneko M, Shikata H, Matsukage S, Maruta M, Shinomiya H, Suzuki T, Saijo M, et al. A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system. J Infect Chemother. 2018;24:292–7.

14. Bord AM, Bondi A, Basile F, Vacante M. Diagnosis and treatment of hypothyroidism in old people: a new old challenge. Wien Klin Wochenschr. 2015;127:161–7.

15. Montesinos MOD, Pellizas CG. Thyroid hormone action on innate immunity. Front Endocrinol (Lausanne). 2019;10:350.